CCM
KROS icon

CAAS Capital Management’s Keros Therapeutics KROS Stock Holding History

CAAS Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-91,296
Closed -$6.44M – 1283
2020
Q4 		$6.44M Buy
+91,296
New +$5.75M 0.06% 273

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

CAAS Capital Management's KROS Position: Q1 2021 in Review

CAAS Capital Management sold out of Keros Therapeutics (KROS) in Q1 2021, closing a stake of 91,296 shares — an estimated $6.44M sold.

CAAS Capital Management first reported a position in KROS in Q4 2020 and held it in 1 quarter. The position peaked at $6.44M in Q4 2020. 83 funds tracked by Wall St. Rank hold KROS as of Q1 2021.

  • CAAS Capital Management reported no remaining Keros Therapeutics position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 91,296 Keros Therapeutics shares in Q1 2021, an estimated $6.44M.
  • CAAS Capital Management first reported a position in Keros Therapeutics in Q4 2020 and held it in 1 quarter.
  • CAAS Capital Management's Keros Therapeutics position peaked at $6.44M in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.